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Anti-angiogenic propertiesDuring endochondral bone formation, vascular invasion initiates the replacement of avascular cartilage by
bone. We demonstrate herein that the cartilage-speciﬁc overexpression of VEGF-A164 in mice results in the
hypervascularization of soft connective tissues away from cartilage. Unexpectedly, perichondrial tissue
remained avascular in addition to cartilage. Hypervascularization of tissues similarly occurred when various
VEGF-A isoforms were overexpressed in the chick forelimb, but also in this case perichondrial tissue and
cartilage were completely devoid of vasculature. However, following bony collar formation, anti-angiogenic
properties in perichondrial tissue were lost and perichondrial angiogenesis was accelerated by VEGF-A146,
VEGF-A166, or VEGF-A190. Once the perichondrium was vascularized, osteoclast precursors were recruited
from the circulation and the induction ofMMP9 andMMP13 can be observed in parallel with the activation of
TGF-β signaling. Neither perichondrial angiogenesis nor the subsequent cartilage vascularization was found
to be accelerated by the non-heparin-binding VEGF-A122 or by the VEGF-A166ΔE162-R166 mutant lacking a
neuropilin-binding motif. Hence, perichondrial angiogenesis is a prerequisite for subsequent cartilage
vascularization and is differentially regulated by VEGF-A isoforms.© 2009 Elsevier Inc. All rights reserved.Introduction
Among the tissues of mesodermal origin, cartilage is uniquely
avascular and highly resistant to vascular invasion except during
endochondral bone formation (Kuettner and Pauli, 1983). During the
development of the appendicular skeleton, preexisting blood vessels
initially regress from the precartilaginous mesenchyme, after which the
condensing mesenchyme gives rise to cartilage and the surrounding
perichondrium, both of which are devoid of blood vessels (Hallmann et
al., 1987; Shukunami et al., 2008). Following the appearance of
prehypertrophic chondrocytes and bony collar formation, blood vessels
migrate into perichondrial tissue to form the vascularized perichon-
drium (perichondrial angiogenesis) in which the vasculature gains
access to osteoblasts in the developing bony collar. During the
subsequent replacement of cartilage by bone, blood vessels invade the
calciﬁed extracellular matrix (ECM) of hypertrophic chondrocytes
(cartilage vascularization) through the cooperative actions of osteo-
clasts and osteoblasts, thereby facilitating the excavation and remodel-
ing of cartilage ECM in tandem with ossiﬁcation with the marrow
cavities (Colnot, 2005; Karsenty and Wagner, 2002). These sequential,
but distinct angiogenic events occur in a strictly spatio-temporally
deﬁned manner during endochondral bone formation.
It is widely accepted that a balance between angiogenesis
stimulators and inhibitors regulates the angiogenic switching of. Shukunami).
l rights reserved.tissues under a variety of physiological or pathological conditions
(Folkman, 1995). In most cases, the elevated expression of VEGF-A
potently induces the initiation and progression of angiogenesis
(Carmeliet and Jain, 2000; Shibuya and Claesson-Welsh, 2006).
Indeed, the upregulation of VEGF-A in cartilage occurs concomitantly
with the vascularization of cartilage during development: VEGF-A is
only marginally expressed in avascular cartilage, but its levels are
elevated transiently in the perichondrium and later persistently in the
late hypertrophic/calciﬁed cartilage (Gerber et al., 1999). A complete
lack of vascular invasion of cartilage is observed in Runx2-null mice
that are deﬁcient in VEGF-A expression in chondrocytes, although
perichondrial angiogenesis is not signiﬁcantly affected in these
animals (Zelzer et al., 2001). Mice lacking VEGF-A in their cartilage
show a delayed vascular invasion into cartilage (Haigh et al., 2000).
These ﬁndings suggest that VEGF-A acts as a key regulator in the
stimulation of cartilage vascularization.
Of the several identiﬁed alternatively transcribed VEGF-A isoforms,
murine chondrocytes express at least VEGF-A120, VEGF-A164, and
VEGF-A188, which differ in their potential to bind to heparan sulfate
proteoglycans (HSPGs) and neuropilins (Nrps) but stimulate endothe-
lial growth and angiogenesis in connective tissues alike. As previously
reported, VEGF-A164 or VEGF-A188 is required for metaphyseal vascular-
ization, whereas VEGF-A120 or VEGF-A164 plays an important role in
epiphyseal cartilage angiogenesis (Maes et al., 2002, 2004; Zelzer et al.,
2002). On the other hand, the overexpression of quail VEGF-A122,
corresponding to mouse VEGF-A120, fails to induce accelerated vascular
invasion into cartilage despite hypervascularization of the surrounding
197A. Takimoto et al. / Developmental Biology 332 (2009) 196–211mesenchyme (Flamme et al., 1995), implying that an angiogenic shift in
the VEGF-A balance alone cannot trigger the angiogenic switch in
cartilage. Hence, it is likely that some permissive conditions for angio-
genesis have to be established prior to vascular invasion into cartilage
matrix and in association with the elevation of VEGF-A expression
levels.
To investigate the cellular and molecular events associated with
angiogenic switching during endochondral bone formation, we
utilized a VEGF-A mediated gain of function approach. We generated
transgenic founder mice overexpressingmurine VEGF-A164 in cartilage
under the control of the Col11a2 promoter/enhancer. We also
overexpressed four VEGF-A splice variants, VEGF-A122, VEGF-A146,
VEGF-A166, and VEGF-A190 in the chick forelimb by the in ovo
electroporation of retroviral vectors. We found from our experiments
that perichondrial tissue along with immature cartilage exhibits a
robust resistance to vascular invasion from the hypervascularized
surrounding mesenchyme. By analyzing the differential vascular
responses to four splice variants of VEGF-A and their mutant forms
in the developing chick forelimb, we demonstrate that the binding
motifs for heparin and Nrp are required for perichondrial angiogenesis
that is a prerequisite for subsequent MMP9 and MMP13 mediated
cartilage vascularization. We also show that TGF-β signaling may
participate in this latter step as important mediators of MMP9 or
MMP13 expression in osteoblasts or chondrocytes.
Materials and methods
Reagents
Recombinant human vascular endothelial growth factor165
(rhVEGF165), recombinant human ﬁbroblast growth factor-2 (rhFGF2),
recombinant human transforming growth factor β1 (rhTGF-β1), β2
(rhTGF-β2), or β3 (rhTGF-β3), recombinant human bone morphogenic
protein 4 (rhBMP4), or 6 (rhBMP6), recombinant mouse growth
differentiation factor 5 (rmGDF5), and recombinant mouse VEGF164
(rmVEGF164) were purchased from R&D systems. Human parathyroid
hormone related protein 1-141 (PTHrP) is a generous gift from Dr. T. J.
Martin (St. Vincent’s Institute of Medical Research).
Eggs and embryos
Fertile White Leghorn (Gallus gallus) chicken eggs were obtained
from Takeuchi Farm (Nara, Japan). Chick embryos at different stages of
development were obtained by incubation of fertilized eggs at 38 °C
and staged according to the method described by Hamburger and
Hamilton (1992). Mice were purchased from Shimizu Laboratory
Supplies Co., Ltd. or CLEA Japan, Inc. C57BL/6×C3H F1 females of
4 weeks of age were superovulated and mated with proven stud
C57BL/6×C3H F1 males. Fertilized eggs were subsequently collected
from the oviducts of the F1 females and used for microinjection. All of
these procedures were approved by the Animal Care Committee of the
Institute for Frontier Medical Sciences, Kyoto University and conform
to institutional guidelines for the study of vertebrates.
RT-PCR
RT-PCR analysis of chicken VEGF-A variants and their receptors was
performedusing 5 μg of total RNA reverse transcribedwith SuperScript
II reverse transcriptase (Invitrogen). PCR ampliﬁcations were per-
formed for 35 cycles using the gene speciﬁc primers listed in Table S1.
Construction of Col11α2–VEGF-A164
The entire coding region of mouse VEGF-A164 was ampliﬁed from
Mouse 11-day Embryo Marathon-Ready cDNA (Clontech) using the
speciﬁc primers 5′-ATAAGAATGCGGCCGCGAAACCATGAACTTT-CTGCTCTC-3′ (F) and 5′-GTGCAGTAGCGGCCGCGGTGAGAGG-
TCTGGTTCCCG-3′ (R). To generate the Col11α2–VEGF-A164 construct,
mouse VEGF-A164 cDNA was inserted into the NotI site of the p742-Int
vector containing the promoter and intronic enhancer of the mouse
Col11a2 gene (Tsumaki et al., 1996).
Generation of transgenic mice
The puriﬁed Col11α2–VEGF-A164 transgene was injected into the
pronuclei of fertilized eggs from C57BL/6×C3H F1 mice as described
previously (Hogan et al., 1994). Injected founder embryos were
dissected and analyzed at E12.5 or E13.5. Transgene positive embryos
were identiﬁed by PCR using genomic DNA extracted from the yolk sac
as previously described (Sasaki et al., 1997).
Retrovirus construction and production
The coding regions of the chicken VEGF-A122, VEGF-A146, VEGF-A166,
and VEGF-A190 genes were ampliﬁed by PCR using the primers forward
5′-CCATGAACTTTCTGCTCACTTGG-3′ and reverse 5′-CTGCTCACCGTC-
TCGGTTTTTC-3′. The coding region of each splice variant was also am-
pliﬁed using the above speciﬁc primers harboring NotI sites at each 5′
end. To generate N-terminal FLAG-tagged VEGF-A splice variants, each
coding region was ampliﬁed using the forward primer 5′-CCCAAGCTT-
GCTCCGGCCCTGGGGGATG-3′ and reverse primer 5′-CCCAAGCTTGCTC-
ACCGTCTCGGTTTTTCAC-3′. The ampliﬁed products were subsequently
digested with HindIII and ligated to a 3 X FLAG fragment containing a
preprotrypsin leader sequence derived fromp3XFLAG-CMV-8 (Sigma, St
Louis, MO). To generate VEGF-A166ΔE162-R166, the coding sequence was
ampliﬁed with the primers 5′-ATAAGAATGCGGCCGCCATGAACTTTCT-
GCTCACTTG-3′ (F) and 5′-ATAAGAATGCGGCCGCTCAACATCTGCAA-
GTGCGCTCG-3′ (R). The PCR-generated products were then digested
with NotI and subcloned into pBlueScript II SK+ (Stratagene). To ge-
nerate VEGF-A166R125A/R160A, site-directed mutagenesis was per-
formed with primers for R125A 5′-TTTGTACAAGATCCCCAGACC-3′
(F) and 5′-CAAGTGCTTTGCCCTCTCTGAG-3′ (R), and for R160A5′-GCGC-
ACTTGCGCATGTGAAAAAC-3′ (F) and 5′-TCGTTTAACTCAAGCTGCCTC-3′
(R). The coding regionswere then subcloned into theRCASBPA retroviral
vector. Chick embryonic ﬁbroblasts (CEFs) were transfected with these
retroviral constructs using FuGENE6 (Roche). After two passages, the
medium was replaced with fresh αMEM (Sigma) supplemented with
0.5% fetal bovine serum(FBS).After 24h, themediumwasharvested and
the virus was concentrated using Centricon Plus-20 columns (Millipore
Corporation, Billerica, MA).
In ovo electroporation
Fertilized chicken eggs were incubated until the embryos reached
Hamburger–Hamilton stages 15–16. A small window was opened for
access and phosphate-buffered saline (PBS) was poured over the
embryo to obtain an appropriate level of resistance (b0.5Ω). A CUY-21
electroporator (Gene System) was used according to a previously
reported method (Ogura, 2002). A DNA solution of retroviral vector
(5 μg/μl) was added to the pCX-EGFP vector (5 μg/μl) at a 2:1 ratio and
this mixture was then injected using a sharp glass pipette into the
lateral plate mesoderm under the right forelimb bud. Electric pulses
were then applied (9 V, 30 ms pulse-on, 70 ms pulse-off, repeated
twice) after the injection of the DNA.
India ink injection
Embryos were injected with a 1:2 dilution of india ink in PBS into
the extraembryonic vitelline vein with FemtoJet (Eppendorf) using a
pulled microcapillary pipette (Narishige). For observations of gross
morphology, embryos were ﬁxed in 4% paraformaldehyde/PBS (PFA/
PBS) and cleared in 30% glycerol/PBS.
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The antisense and sense RNA probes for each gene were
transcribed from plasmids with a digoxygenin (DIG) RNA labeling
kit (Roche). For RNA probes, the cDNAs were ampliﬁed by RT-PCR
based upon their sequence information in GenBank as follows: ChM-I
(NM204810), MMP9 (AF222690), MMP13 (AF070478), Nrp1
(D45416), Nrp2 (AB090235), Semaphorin3F (Sema3F) (NM204258).
Type I collagen alpha 2 (Col1a2) and type II collagen alpha 1 (Col2a1)
cDNAs were generously provided by Dr. B. R. Olsen (Harvard Medical
School). Virus envelope (env) cDNA was generously provided by Dr. T.
Ogura (Tohoku University), and used as templates for the generation
of their respective RNA probes.
Immunostaining
Cartilage was stained with anti-collagen type II antibody (diluted
1:100; ROCKLAND), the vascular endothelium in mouse was stained
with anti-mouse CD31 antibody (diluted 1:800; BD PharMingen), the
perichondriumwas stained with the M1-B4 antibody against tenascin
(diluted 1:800; Developmental Studies Hybridoma Bank) and the
FLAG-tag was stained with an afﬁnity puriﬁed anti-FLAG M2 antibody
(diluted 1:500; Sigma). Viral gag protein was stained with AMV-3C2
hybridoma culture supernatant (diluted 1:10; Developmental Studies
Hybridoma Bank). Activation of TGF-β signaling was visualized by
anti-phopho-Smad2 antibody staining (diluted 1:500; Millipore).
Cryosectionswere incubatedwith each respective primary antibody at
4 °C overnight and washed. For DAB staining, the sections were
reincubated with biotinylated horse anti-mouse secondary antibody
(Vector Laboratories) for 30 min and endogenous peroxidase activity
was inactivated by incubation in 0.3% H2O2/methanol for 30 min.
Sections were then washed and incubated with ABComplex, and
immunoreactivity was detected using the substrate kit for peroxidase
of DAB (Vector Laboratories). The sections stained withM1-B4 by DAB
were counterstained in 1% alcian blue at pH 1. For immunoﬂuorescent
analysis, the sections were incubated with an appropriate secondary
antibody labeled with Alexa ﬂuor 488 or Alexa ﬂuor 594 (diluted
1:300; Molecular Probes).
Alcian blue, toluidine blue and TRAP staining
For alcian blue staining, embryos were ﬁxed in 5% trichloroacetic
acid for 3 h and washed three times with distilled water. The embryos
were then stained with 0.1% alcian blue in 70% ethanol containing
0.1% HCl for 3 h and destained in 70% ethanol containing 0.1% HCl.
After twice dehydrating in 100% ethanol for 1 h, the samples were
cleared and stored in methyl salicylate. For toluidine blue staining,
deparafﬁnized and/or hydrated sections were stained with 0.05%
toluidine blue solution (pH 4) for 2 to 10 min. For TRAP staining,
sections were equilibrated in acetate buffer (0.1 M sodium acetate,
pH 5) for 20 min and then incubated in acid phosphatase substrate
buffer (0.007% pararosanilin chloride, 0.014% sodium nitrite, 0.06%
naphthol AS-TR, and 100 mM sodium tartrate in acetate buffer) for
60 min at 37 °C.
Cell culture
Following trypsin and collagenase digestion, CEFs and chondro-
cytes were isolated from leg tendons and from distal tibiotarsal
cartilage of stage 41 chick embryos (Shukunami et al., 2006). These
isolated CEFs and chondrocytes were grown in αMEM medium
containing 10% FBS in a humidiﬁed atmosphere of 5% CO2 in air.
Osteoblasts were isolated from the calvariae of day 16 chick embryos
using four sequential 15 minute digestions in 0.05% trypsin and 0.1%
collagenase P (Roche) at 37 °C, as previously reported (Gerstenfeld
et al., 1987). Calvarial cells from fractions 2–4 were collected andgrown in DMEM (Wako) containing 10% FBS. After reaching
conﬂuence, BGJb medium (Invitrogen) supplemented with 50 μg/
mL ascorbate and 5 mM β-glycerophosphate was used to induce
differentiation of the cells.
Northern blot analysis
Ten or 15 μg of total RNA was denatured with 6% formaldehyde,
fractionated using 1% agarose gel electrophoresis, and transferred
onto Nytran membranes with a Turboblotter (Schleicher and Schuell).
Hybridization was performed as previously described (Shukunami
et al., 2006). To generate speciﬁc probes, cDNAs were ampliﬁed by RT-
PCR based on sequence information in GenBank i.e. Aggrecan (Agg)
(U78555), Alkaline phosphatase (ALP) (U19108), MMP2 (U07775),
Osteocalcin (OC) (NM205387), Osteopontin (OP) (NM20535), type X
collagen alpha 1 (Col10a1) (M13496), VEGF-A (AB011078). Runx2
cDNA was generously donated by Dr. A. Lassar (Harvard Medical
School). Other probes were obtained from the same cDNAs that were
used as templates to generate the RNA probes mentioned above.
Western blot analysis
Cell lysates were harvested in 1×SDS sample buffer containing
50 mM Tris–HCl (pH 6.8), 50 mM DTT, 2% SDS, and 10% glycerol.
Forelimbs of chick embryos were homogenized in buffer containing
8 M urea, 50 mM Tris–HCl (pH 8.0), and 1 mM EDTA. The
concentration of total protein was determined with a BCA protein
assay kit (Pierce) and 10 μg of tissue extracts were diluted in 4×SDS
sample buffer. Samples were electrophoresed on 12% SDS-polyacry-
lamide gels and transferred to nitrocellulose membrane (Bio-Rad).
After preincubationwith blocking buffer (3.2% nonfat milk in TBS), the
membranes were incubated with rabbit anti-Smad2 antibody (diluted
1:1000; Zymed), rabbit anti-phospho-Smad2 antibody (diluted
1:2000; Millipore), or mouse anti-FLAG M2 monoclonal antibody
(1:5000, Sigma) followed by incubation with horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG antibody or HRP-conjugated anti-
mouse IgG antibody (GE Healthcare). Peroxidase activity was detected
and visualized using the ECL plus system (GE Healthcare), according
to the manufacturer's instructions.
Results
Cartilage and perichondrial tissue are strongly resistant to vascular
invasion
VEGF-A190/189/188 (chicken/human/mouse) is encoded by exons
1–8, VEGF-A166/165/164 lacks exon 6, VEGF-A146/145/144 lacks exon 7,
and VEGF-A122/121/120 lacks exons 6 and 7 (Fig. S1A). In limb, tibia,
sternal cartilage, and in cultured tibial and sternal chondrocytes, four
VEGF-A variants that differed in length between chicken and mouse
by two amino acids were detected by RT-PCR (Fig. S1B).
As we have previously reported (Shukunami et al., 2008),
avascular perichondrial tissue is present between the surrounding
vascularized connective tissue and the non-hypertrophic cartilage
along the diaphysis (arrows in Fig. 1A). To test the anti-angiogenic
resistance of these avascular regions (cartilage and perichondrial
tissue), we generated transgenic mice overexpressing mouse VEGF-
A164 in cartilage under the control of the mouse Col11a2 promoter/
enhancer (Tsumaki et al., 1996; Tsumaki et al., 2002). The efﬁciencies
of transgenic production were 36% (n=19) at E12.5 and 25%
(n=107) at E13.5, respectively. In a wild type embryo at E12.5, the
expression of VEGF-A164 was undetectable in the cartilaginous
elements of the forelimb by in situ hybridization (Fig. 1B). In contrast,
expression of VEGF-A164 in the cartilaginous elements at E12.5 was
detectable (Fig. 1G), validating the speciﬁc expression of the trans-
genic cartilage under the control of the mouse Col11a2 promoter/
Fig. 1. Robust resistance to vascular invasion in mouse cartilage and perichondrial tissue. (A) Both cartilage (purple double arrow) and perichondrial tissue (green double arrow)
are avascular and are surrounded by vascularized connective tissue. (B, G) VEGF-A expression in the forelimb of an E12.5 wild type (B) and a Col11α2–VEGF-A164 transgenic mouse
embryo (G) detected by in situ hybridization. (C, D, H, I) Double immunostaining for CD31 (red) and Col2 (green) in the forelimb of an E12.5 wild type (C, D) and a Col11α2–
VEGF-A164 transgenic mouse embryo (H, I). (E, J) Lateral views of an E13.5 wild type (E) and a Col11α2–VEGF-A164 transgenic mouse embryo (J). Arrowheads in (J) indicate
hemorrhage. (F, K) Double immunostaining for CD31 (red) and Col2 (green) in the forelimb of an E13.5 wild type (F) and a Col11α2–VEGF-A164 transgenic mouse embryo (K). The
avascular perichondrial region is indicated by asterisks (C, D, F, H, I, K). d, digit; u, ulna; r, radius. Scale bars, 100 μm.
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phalangeal or carpal cartilages and their perichondrial tissues are
avascular (asterisks in Figs. 1C, D, F), whilst the soft connective tissues
outside of perichondrial tissue were found to be vascularized as
evidenced by their positive staining for CD31 (Figs. 1C, D, F). In
transgenic mouse embryos overexpressing VEGF-A164 in cartilage
(Col11α2–VEGF-A164) at E12.5 and E13.5 (Fig. 1J), both cartilage and
perichondrial tissue remained avascular against a concentration gra-
dient of VEGF-A164 (asterisks in Figs. 1H, I, K). In contrast, hyper-
vascularization was observed in the surrounding loose connective
tissue and muscle, suggesting that these tissues are permissive for
angiogenesis (Figs. 1H, I, K). Similar phenotypes were observed in
transgenic founder embryos overexpressing VEGF-A164 in cartilage
under the control of the mouse Col2a1 promoter/enhancer (Col2α1–
VEGF-A164). The efﬁciency of transgenic production was 3.2% (n=31)
at E13.5 or 3% (n=33) at E14.5 probably due to the lethal vascular
phenotype (data not shown). Thus, these transgenic approaches
revealed that both cartilage and perichondrial tissue are highly
resistant to vascular invasion.
In our transgenic experiments, increased permeability and
hemorrhage, were observed in association with the progression of
cartilage formation, as shown in Col11α2–VEGF-A164 transgenic
founder embryos at E13.5 (Fig. 1J). At this embryonic day, 4 of 12
Col2α1-VEGF-A164 transgenic embryos with vascular phenotypes
were found to be dead (data not shown). To further examine the
anti-angiogenic properties of tissues during endochondral bone
formation, we took advantage of the in ovo electroporation gene
transfer method using chick embryos (Ogura, 2002). Retroviraloverexpression of each of the four VEGF-A variants (VEGF-A122,
VEGF-A146, VEGF-A166, and VEGF-A190) in the chick forelimb similarly
induced hypervascularization in mesenchymal tissues except for
cartilage (arrowheads in Figs. 2A, B, D, F, H). Although skeletal
patterning was not signiﬁcantly affected in the VEGF-A122-overexpres-
sing limb (Fig. 2C), curvature of the ulna was observed in limbs
overexpressing VEGF-A146, VEGF-A166 or VEGF-A190 (arrowheads in
Figs. 2E, G, I). Expression of GFP was clearly detected from 72 h
after electroporation of RCAS-EGFP into the right forelimb (data not
shown) and this GFP expression persisted throughout the entire
forelimb at stage 32, 120 h after electroporation, due to the
propagation of the retrovirus (Fig. 2J). In EGFP-overexpressing
chick embryos, no signiﬁcant abnormalities were detected in the
vascular network as evidenced by india ink injections (Fig. 2K).
Western blot analysis revealed that each VEGF-A isoform was
expressed in the electroporated forelimb at relatively similar levels
(Fig. 2L).
Perichondrial angiogenesis is regulated in a VEGF-A isoform-speciﬁc
manner
At stage 29, blood vessels were present only outside of perichon-
drial tissue surrounding the non-hypertrophic ulnar cartilage in the
contralateral left forelimb (red arrowheads in Fig. 3A). Likewise,
despite the increased vascular density in the surrounding mesench-
yme, blood vessels were detected just only outside perichondrial
tissue in the right forelimb overexpressing VEGF-A122 or VEGF-A166
(red arrowheads in Figs. 3B, C), clearly indicating that perichondrial
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this stage.
At stage 32, early hypertrophic chondrocytes appeared in the
center of the ulna (Fig. 3D), but blood vessels were still found outside
the perichondrium (red arrowheads in Fig. 3G). In contrast, migration
of the vascular network into the perichondrium was observed in
forelimbs overexpressing VEGF-A146 (red arrowheads in Fig. 3K),
VEGF-A166 (Fig. 3F, red arrowheads in Fig. 3I) or VEGF-A190 (red
arrowheads in Fig. 3L). Acceleration of perichondrial angiogenesis was
observed in the ulna or radius in each of the forelimbs overexpressing
VEGF-A146, VEGF-A166, or VEGF-A190 (Table 1). Accelerated perichon-
drial angiogenesis of the ulna in Col11α2–VEGF-A164 transgenic mice
was also detected in three of seven embryos at E12.5 and two of three
embryos at E13.5 (Fig. S2, data not shown). Surprisingly, blood vessels
failed to penetrate perichondrial tissue to gain direct access to the
bony collar and cartilage in the forelimb overexpressing VEGF-A122Fig. 2. Robust resistance to vascular invasion in cartilage of the developing chick forelimb
forelimb (arrow) of a stage 32 chick embryo visualized with india ink. (B, D, F, H) At stage 3
right forelimbs retrovirally overexpressing VEGF-A122, VEGF-A146, VEGF-A166, or VEGF-A19
(arrowheads) and in the contralateral digits. (C, E, G, I) Skeletal preparations of stage 32 co
VEGF-A190. Arrowheads in (E), (G), and (I) indicate bending of the ulna. (J, K) Contralateral le
ink. (L) Detection of VEGF-A122, VEGF-A166, and VEGF-A190 in the right electroporated (R) or l
a FLAG-tagged VEGF-A isoform overexpressing forelimb or contralateral forelimb at stage 32
anti-FLAG-antibody. u, ulna; r, radius.(Fig. 3E, red arrowheads in Fig. 3H, Table 1), although perichondrial
avascular space in the VEGF-A122-overexpressing limb became
narrower than that of the contralateral side (Fig. 3H).
In the contralateral limb at stage 32, Col1a2 expressionwas evident
in the adjacent region of cartilage, indicating formation of the bony
collar, but neither MMP9 nor MMP13 was expressed in the perichon-
drial region (Fig. 3G). In the VEGF-A122-overexpressing forelimb, weak
positive Col1a2 signals were detected, but MMP9 and MMP13
expression were not evident (Fig. 3H). However, MMP9 and MMP13
expression were induced in the VEGF-A146-, VEGF-A166-, or VEGF-A190-
overexpressing limb (Fig. 3I, data not shown), particularly in the inner
layer of the perichondrial region just adjacent to the future diaphysis.
In the metaphyseal region of the VEGF-A146-, VEGF-A166-, or VEGF-
A190-overexpressing forelimb, MMP9 but not MMP13 expression was
detected (Fig. 3J, data not shown), suggesting that MMP9 expression
occurs more widely than MMP13 expression.. (A) Increased angiogenesis and permeability in the VEGF-A122-overexpressing right
2 in the chick embryo, hypervascularization and hyperpermeability are observed in the
0. Avascular regions are visible in the digits overexpressing these VEGF-A variants
ntralateral left and right forelimbs overexpressing VEGF-A122, VEGF-A146, VEGF-A166, or
ft and EGFP-overexpressing right forelimb of a stage 32 chick embryo injected with india
eft contralateral (L) forelimb bywestern blot analysis. Urea-extracts were prepared from
. Ten μg of tissue extracts was separated by SDS-PAGE and each isoformwas detected by
Fig. 3. Acceleration of perichondrial angiogenesis in the chick forelimb is stimulated by VEGF-A146, VEGF-A166, or VEGF-A190. Semi-serial sections were prepared for toluidine blue
staining, immunostaining of tenascin with alcian blue, and in situ hybridization analysis of Col1a2, MMP9, MMP13, and env using india ink-injected forelimbs. (A–C) At stage 29,
blood vessels (red arrowheads) are present outside of the perichondrial region of the contralateral forelimb (A), or the forelimb overexpressing VEGF-A122 (B), or VEGF-A166 (C).
(D–F) At stage 32, invasion by the blood vessels of the inner layer of the perichondrial region is not observed in the contralateral (D) or VEGF-A122-overexpressing forelimb (E) but is
seen in the VEGF-A166-overexpressing forelimb (F). (G–J) Magniﬁed images corresponding to the boxed regions in (D–F). (K, L) The diaphyseal regions of stage 32 ulna
overexpressing VEGF-A146 (K) and VEGF-A190 (L). Red and blue arrowheads in (G–L) indicate the vasculature and mRNA expression of each gene, respectively. u, ulna; TB, toluidine
blue; TN, tenascin. Scale bars, 100 μm.
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At stage 33, cartilaginous skeletal elements of the VEGF-A166- or
VEGF-A190-overexpressing right forelimbwere found to be fragmented
at the middle (arrows, right in Figs. 4B, C) but no such fragmentation
was observed in the contralateral left forelimbs (left in Figs. 4A–C) or
VEGF-A122-overexpressing right forelimb (right in Fig. 4A). At stage 34,
perichondrial angiogenesis of the ulna took place in the contralateralforelimb (Figs. 4D–F). In a normal embryo at stage 37, cartilage
vascularization was observed at the center of the radius or ulna
(arrows in Fig. S4A). At the site of vascular invasion (Fig. S4B), tartrate-
resistant acid phosphatase (TRAP)-positive osteoclasts (red arrow-
heads in Fig. S4C) were noted, some of which expressed MMP9 (red
arrowheads in Fig. S4D).MMP9- andMMP13-positive signalswere also
detectable in TRAP-negative cells (blue arrowheads in Figs. S4D, E).
In the VEGF-A122-overexpressing right forelimb, perichondrial
angiogenesis occurred normally at stage 34 (Figs. 4G, H), but an
Table 1
Effects of VEGF-A isoforms upon perichondrial angiogenesis and the upregulation of MMP9 and MMP13.
Contralateral limb VEGF-A122 VEGF-A146 VEGF-A166 VEGF-A190 VEGF-A166 R125A/R160A VEGF-A166 ΔE162-R166
No. of embryos examined 60 15 4 17 13 6 5
No. with perichondrial angiogenesis 0 0 4 17 13 6 0
No. with upregulation of MMP9/13 0 0 4 17 13 6 0
The RCAS vector carrying each VEGF-A isoform or mutant was electroporated into the right forelimb of the chick embryo at stages 15–16. The embryos were harvested at stage 32 for
in situ hybridization analysis. Contralateral left forelimbs served as controls. Numbers (No.) of embryos showing perichondrial angiogenesis and upregulation ofMMP9 and MMP13
(MMP9/13) in the ulna or radius are indicated.
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were observed near the bony collar, compared with those of the
contralateral side (arrowheads in Figs. 4E, F, H, I). When VEGF-A146
was overexpressed, cartilage was completely separated into twoFig. 4. Accelerated cartilage vascularization in the chick forelimb is induced by VEGF-A146,
the right forelimbs overexpressing VEGF-A122, VEGF-A166, or VEGF-A190 are shown. (D–U) I
staining (D, G, J, L–O), TRAP staining (F, I, K, P), and in situ hybridization analysis of Col1a2 (E
VEGF-A122 (G–I), VEGF-A146 (J, K), VEGF-A166 (N–U) or VEGF-A190 (L) and the contralateral sid
diaphyseal regions corresponding to the boxed areas in (D), (G), (J), and (N) are shown in
cartilage. Red arrowheads in (E, H) indicate invading vasculature in the bony collar withi
surrounding cartilage. The vascularized tissue is indicated by dotted lines (O–U). ca, cartilapieces as a result of extensive excavation and degradation of the ECM
in the diaphysis (arrows in Fig. 4J). Numerous TRAP-positive cells
were also observed at the site of accelerated vascular invasion (Fig.
4K). Fragmentation of cartilage was further noted in the VEGF-A166- orVEGF-A166, or VEGF-A190. (A–C) Skeletal preparations of stage 33 contralateral left and
ndia ink-injected forelimbs at stage 34 were processed as sections for toluidine blue
, H, Q),MMP9 (R),MMP13 (S), Col2a1 (T), or ChM-I (U). Right forelimbs overexpressing
e (D–F, M) to the VEGF-A122- or VEGF-A166- overexpressing forelimb are presented. The
(E, F), (H, I), (K), and (O–U), respectively. Red arrows indicate vascular invasion into
n the perichondrium. Blue arrowheads in (O, Q) indicate Col1a2-positive osteoblasts
ge; h, humerus; r, radius; u, ulna; TB, toluidine blue. Scale bars, 100 μm.
Table 2
Effects of VEGF-A isoforms upon cartilage vascularization and the expression of MMP9 and MMP13.
Contralateral forelimb VEGF-A122 VEGF-A146 VEGF-A166 VEGF-A190 VEGF-A166 R125A/R160A VEGF-A166ΔE162-R166
No. of embryos examined 55 14 6 16 15 ND 4
No. with cartilage vascularization 0 0 1 4 5 ND 0
No. with expression of MMP9/13 + (19/19) ++ (4/4) +++ (1/2) +++ (3/7) +++ (2/6) ND ND
++++ (1/2) ++++ (4/7) ++++ (4/6)
The RCAS vector carrying each VEGF-A isoform was electroporated into the right forelimbs of the chick embryos at stages 15–16. The embryos were harvested at stages 33–34 for
alcian blue staining or in situ hybridization analysis. Contralateral left forelimbs served as controls. Numbers (No.) of embryos showing cartilage vascularization and upregulation of
MMP9/13 in the ulna or radius are indicated. The MMP9/13 expression levels were compared with those in the contralateral forelimb. ND, not determined.
203A. Takimoto et al. / Developmental Biology 332 (2009) 196–211VEGF-A190-overexpressing limb (Figs. 4N or L, respectively), whereas
the contralateral side remained avascular (Fig. 4M). A slight
metachromasia (Fig. 4O), invasion of TRAP-positive cells (Fig. 4P),
and strong expression of MMP9 and MMP13 (Figs. 4R, S) were
observed in the tissues showing vascular invasion (area surrounded
by the dotted line in Figs. 4O–U). Col1a2 was expressed in the
mesenchyme surrounding cartilage (blue arrowheads in Figs. 4O, Q),
but was not detectable in the invaded tissue (Fig. 4Q). The expression
of Col2a1 and Chondromodulin-I (ChM-I), a cartilage derived angio-
genesis inhibitor (Hiraki et al., 1997), was detectable in both cartilage
and the invaded tissue (Figs. 4T, U). Unlike the accelerated
perichondrial angiogenesis induced by VEGF-A146, VEGF-A166 or
VEGF-A190, the acceleration of cartilage vascularization by these
VEGF-A isoforms was only observed in the forelimb expressingFig. 5. A uniform distribution of VEGF-A122 and VEGF-A166 in cartilage. (A) Vascularity of the l
stage 32 visualized by india ink. Magniﬁed images of the boxed region in (A) are shown in (C
(B) and (D), respectively. (E–N) In the right forelimb overexpressing FLAG-VEGF-A122 or FLAG
and (J). (F, K) Immunostaining for viral gag protein shows propagation of retroviral infectio
shown in (G–I) and (L–N), respectively. Blood vessels are observed outside the perichond
present in close proximity to cartilage in the forelimb overexpressing FLAG–VEGF-A166 (L).
VEGF-A122 (H) or FLAG–VEGF-A166 (M). In semi-serial sections, tenascin is detected in the E
ﬁeld. Scale bars, 100 μm.MMP9 and MMP13 at a high level (Table 2). We thus speculate that
the threshold level for cartilage vascularization is higher than that for
perichondrial angiogenesis.
Perichondrial angiogenesis is accelerated by the heparin-binding
impaired VEGF-A166 mutant
Heparan sulfate proteoglycans (HSPGs) act as co-receptors for
VEGF-A signaling, but VEGF-A122 lacks the heparin-binding motif (Fig.
S1A) and is freely diffusible (Houck et al., 1992). In the postnatal
retina, endothelial tip cells have been shown to migrate in response to
a concentration gradient of VEGF-A164 generated by its binding of
heparin or HSPGs (Gerhardt et al., 2003). A large number of HSPGs
such as perlecan and syndecan are present in the developing cartilageeft forelimb (contralateral to the VEGF-A122-overexpressing right forelimb shown in E) at
) and (D). Immunostaining with anti-gag antibody and anti-FLAG antibody are shown in
-VEGF-A166, hypervascularization of mesenchyme surrounding cartilage is shown in (E)
n in the entire right forelimb. Magniﬁed images of the boxed region in (E) and (J) are
rial region in the forelimb overexpressing FLAG–VEGF-A122 (G), whereas vascularity is
Immunostaining with anti-FLAG antibodies indicates a uniform distribution of FLAG–
CM of cartilage and perichondrium (I, N). u, ulna; ca, cartilage; TN, tenascin; BF, bright
Fig. 6. Acceleration of perichondrial angiogenesis in chick forelimbs overexpressing the VEGF-A166 mutant with impaired heparin-binding activity. (A) Schematic representation of
VEGF-A166R125A/R160A. The positions of the disulﬁde bonds between Cys residues were deduced from the human VEGF-A165 protein. (B–H) VEGF-A166R125A/R160A was
overexpressed in the right forelimb. (B) India ink-injected stage 32 contralateral left or right forelimb overexpressing VEGF–A166R125A/R160A. The right forelimb was sectioned for
toluidine blue staining (C), immunostaining of tenascin with alcian blue (D, E), and in situ hybridization analysis of env (F), MMP9 (G), and MMP13 (H). A magniﬁed image of the
boxed region in (D) is shown in (E), and in situ hybridization analyses of semi-serial sections in (F–H) are shown for the corresponding area to (E). Red and blue arrowheads in (E)
and in (G, H) indicate the vasculature and mRNA expression of each gene, respectively. u, ulna; TB, toluidine blue; TN, tenascin. Scale bars, 100 μm.
204 A. Takimoto et al. / Developmental Biology 332 (2009) 196–211and surrounding perichondrial tissue (Hardingham and Fosang, 1992;
Koyama et al., 1995) andmay contribute to the generation of a VEGF-A
concentration gradient, depending on the heparin afﬁnity of each
isoform. Immunostaining was performed to reveal the localization of
VEGF-A isoforms in the forelimb overexpressing FLAG–VEGF-A122 orFig. 7. Upregulation of Nrp1 in chick forelimbs overexpressing VEGF-A122 or VEGF-A166. India
toluidine blue staining (A, D, G, J) and in situ hybridization analysis of Nrp1 (B, C, E, F, H, I, K, L
stage 32, and VEGF-A166-overexpressing forelimb (J–L) and the contralateral forelimb (G–I) a
in the ulna of the VEGF-A166-overexpressing forelimb (J). The magniﬁed images shown in (B
respectively. Nrp1 expression is detected in blood vessels as marked by carbon particles (blue
overexpressing forelimb (E) compared with the contralateral left forelimb (B). The upregu
without ink injection (C, F). Increased expression of Nrp1 is also detectable in the VEGF-A
participating in the invasion into the perichondrium and cartilage (red arrowheads in K). uFLAG–VEGF-A166 (Fig. 5). Blood vessels can be observed outside
perichondrial tissue in the contralateral (Figs. 5A, C) or FLAG–VEGF-
A122-overexpressing forelimb (Figs. 5E, G), whereas the vasculature is
present in close proximity to cartilage in the forelimb overexpressing
FLAG–VEGF-A166 (Figs. 5J, L). However, a signiﬁcant differentialink injected (A, B, D, E, G–L) or uninjected (C, F) forelimb sections were processed for
). The VEGF-A122-overexpressing forelimb (D–F) and the contralateral forelimb (A–C) at
t stage 33 are shown. Vascular invasion into the perichondrium and cartilage is observed
) or (E) correspond to the boxed region of the semi-serial section shown in (A) or (D),
arrowheads in B, E, H, I, K, L). Increased expression of Nrp1 is detected in the VEGF-A122-
lation of Nrp1 induced by VEGF-A122 is clearly visible in the sections from an embryo
166-overexpressing forelimb (K, L), and this expression is strongly induced in the cells
, ulna; r, radius; TB, toluidine blue. Scale bars, 100 μm.
Fig. 8. Lack of accelerated perichondrial angiogenesis in chick forelimbs overexpressing the VEGF-A166 mutant lacking an Nrp interacting domain. (A) The C-terminal 50 amino acids
of chicken VEGF-A166 are encoded by exons 7–8. The positions of the disulﬁde bonds were deduced from the human VEGF-A165 protein. The Nrp1 interactive motif (E162–R166) is
underlined. (B–H) VEGF-A166ΔE162-R166 lacking the C-terminal ﬁve amino acids encoded by exon 8 (underline in A) was overexpressed in the right forelimb. (B) India ink-injected
stage 32 contralateral left or right forelimb overexpressing VEGF-A166ΔE162-R166. The right forelimb was sectioned for toluidine blue staining (C), immunostaining of tenascin with
alcian blue (D, E), and in situ hybridization analysis of env (F), MMP9 (G), and MMP13 (H). A magniﬁed image of the boxed region in (D) is shown in (E), and in situ hybridization
analyses of semi-serial sections in (F–H) are shown for the corresponding area to (E). Arrowheads in (E) indicate blood vessels outside the perichondrium. u, ulna; TB, toluidine blue;
TN, tenascin. Scale bars, 100 μm.
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observed (Figs. 5H, M), suggesting the absence of a concentration
gradient in forelimbs overexpressing these VEGF-A isoforms in this
case.
Two basic heparin-binding domains (HBDs) are encoded by exons
6 and 7 of the VEGF-A gene, respectively (Krilleke et al., 2007). Site-
directedmutagenesis has revealed that arginines at positions 122,123,
and 158 are critical for the heparin-binding activity of mouse VEGF-
A164 HBD (Krilleke et al., 2007). We thus substituted arginines for
alanines at positions 125 and 160 of chick VEGF-A166 to generate the
chick equivalent (VEGF-A166R125A/R160A) of the mouse double
mutant (VEGF-A164R123A/R158A) i.e. has no detectable binding but
shows a slight reduction in binding to Nrp1 (Fig. 6A). As shown in Fig.
6B, the overexpression of VEGF-A166R125A/R160A resulted in hyper-
vascularization and hyperpermeability of the forelimb (Fig. 6B).
Accelerated perichondrial angiogenesis (Figs. 6C–F) and the upregu-
lation of MMP9/13 (Figs. 6G, H) were also observed upon the
expression of this double mutant form of VEGF-A166.
The Nrp interactive motif of VEGF-A166 is necessary for perichondrial
angiogenesis
Nrp1 and Nrp2 have been shown to modify VEGF-A signaling via
VEGFR-1 or VEGFR-2 (Staton et al., 2007). Nrp1 acts as a co-receptor
for both VEGF-A165 and VEGF-A189, thereby enhancing VEGFR-2
binding and bioactivity (Herve et al., 2008; Soker et al., 1998). At
stage 32, the perichondrium surrounding cartilage (Fig. S3A) and the
developing bony collar were indicated by intense staining of tenascin
(Fig. S3B) and expression of Col1a2 (Fig. S3C), respectively. Nrp1 or
Nrp2 were detected in the vasculature of the surrounding mesench-
yme (red arrow in Figs. S3D, E and arrowheads in Figs. S3H, I). Nrp1
was also found to be weakly expressed around the bony collar
expressing Col1a2 (Figs. S3C, D, J, K), whilst Nrp2 was detectable in
tenascin-positive perichondrial tissue (Figs. S3B, E, L). We also
examined the expression of the class 3 semaphorins that have been
previously shown to interact with Nrps (Staton et al., 2007). Sema3F
was expressed in cartilage and the perichondrium (Figs. S3F, M).
Next, we investigated the expression of Nrp1 in VEGF-A122- or
VEGF-A166-overexpressing forelimbs (Fig. 7). Perichondrial tissue was
found to be devoid of blood vessels in the contralateral (Figs. 7A, G) or
VEGF-A122-overexpressing forelimb (Fig. 7D), whereas cartilagevascularization following accelerated perichondrial angiogenesis
was observed in the VEGF-A166-overexpressing forelimb (Fig. 7J).
Nrp1was found to be expressed in the vasculature of the contralateral
side (blue arrowheads in Figs. 7B, C, H, I). The upregulation of Nrp1 in
the vasculature was detected in forelimbs overexpressing VEGF-A122
(blue arrowheads in Figs. 7E, F) or VEGF-A166 (blue arrowheads in Figs.
7K, L). It should be noted that signiﬁcant upregulation of Nrp1 was
detected in the vascularizing perichondrium and cartilage of VEGF-
A166-overexpressing forelimb (red arrowheads in Fig. 7K). The
expression proﬁles of Nrps and upregulation of Nrp1 expression by
VEGF-A isoforms raise the possibility that the Nrps participate in
angiogenic switching during perichondrial angiogenesis.
To test the possibility that Nrp is involved in perichondrial
angiogenesis, we overexpressed a truncated form of VEGF-A166 lacking
the Nrp-binding motif (VEGF-A166ΔE162-R166) in the right forelimb
(Fig. 8A) (von Wronski et al., 2007). The Nrp-binding motif has been
thought to overlap with the heparin-binding domain in VEGF-A166 or
VEGF-A190. However, recent studies using a small amino acid peptide
have revealed that the C-terminal tail region coded by exon 8 of the
VEGF-A gene might be sufﬁcient to interact with Nrp1 (Jia et al.,
2006), although an additional region encoded by exon 7 (also
necessary for heparin binding) is probably required for formation of
the ligand/receptor complex. Overexpression of VEGF-A166ΔE162-R166
in our hands resulted in hypervascularization and hyperpermeability
of the mesenchyme (Fig. 8B), but blood vessels completely failed to
migrate into perichondrial tissue (Figs. 8C–F), and neither MMP9 nor
MMP13was induced (Figs. 8G, H). These ﬁndings suggest that the Nrp-
binding motif of VEGF-A plays an important role in perichondrial
angiogenesis.
Neither MMP9 nor MMP13 is directly induced by chicken VEGF-A166,
human VEGF-A165, or mouse VEGF-A164, but both are upregulated by
TGF-β isoforms
In the ulna and radius, vascular invasion into cartilage occurs
during stage 37 (Figs. S4A, B). TRAP-positive osteoclasts are derived
from monocytes expressing MMP9 (red arrowheads in Figs. S4C, D).
Interestingly, however, TRAP-negative, MMP9-positive cells were
found at the invasion site (blue arrowheads in Fig. S4D). Prior to the
acceleration of vascular invasion into cartilage induced by VEGF-A146,
VEGF-A166, or VEGF-A190, we observed that perichondrial osteoblastic
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cartilage vascularization had occurred, theseMMPs became detectable
in chondrocytes (Figs. 4R–U). As shown in Fig. S1B, VEGFR-1/2 and
Nrp1/2 were found to be expressed in osteoblasts and chondrocytes,
but it remains unclear whether VEGF-A directly acts on these cells.
Overexpression of EGFP or VEGF-A166 in osteoblasts did not signiﬁ-
cantly affect the cellular morphology (Figs. 9A–C). In addition,
although the MMP13 transcript levels were elevated in association
with osteoblast maturation (Figs. 9D, S5), VEGF-A166 failed to directly
upregulate the mRNA levels of MMP9, MMP13 and MMP2 at any
maturation stage (Fig. 9D, data not shown). Moreover, the expression
of ALP, OP, or OC mRNA was similar between osteoblasts over-
expressing either VEGF-A166 or EGFP (Fig. 9D), indicating that the
maturation of osteoblasts is not altered by VEGF-A166. Thus, we
conclude that VEGF-A166 indirectly induces MMP9 or MMP13 in
osteoblasts in vivo.Fig. 9. Upregulation ofMMP9 andMMP13 expression by TGF-βs in skeletal cells. (A) Chick os
DMEM containing 10% FBS. At 24 h after this inoculation, cells were infected with RCAS–EGFP
up to 22 days. Cellular morphology of osteoblasts infected with RCAS–EGFP (A, B) or RCAS–VE
(day 8) and mature osteoblasts (day 15 or 22) infected with RCAS–EGFP or RCAS–VEGF-A1
Immature osteoblasts at day 7 were treatedwith rhVEGF165 (30 ng/ml), rhFGF2 (10 ng/ml), r
rhBMP6 (100 ng/ml), or rmGDF5 (500 ng/ml) for 24 h, and total RNA was then prepared
northern blot. (F) Chick chondrocytes isolated from distal tibia were seeded at a density of 2×
9, chondrocytes were treated with rmVEGF164 (30 ng/ml), rhTGF-β2 (10 ng/ml), PTHrP (1
analysis of MMP2, MMP9, Col2a1, Col10al, or Agg is shown. Ten μg (D, E) or 15 μg (F) of RNA
staining. (G) Chick tibial chondrocytes on day 5 (Chon.) or calvarial osteoblasts on day 17 (O
cells were detected by western blot analysis.To next identify the factors that induce the expression of these
MMPs, we screened several molecules based on previous reports of
their expression in developing cartilaginous bone primordia and
analyzed their effects on the mRNA levels of MMP9 or MMP13 in
osteoblasts or chondrocytes. The addition of rhVEGF-A165, rhBMP4,
rhBMP6, or rmGDF5 failed to upregulateMMP9 andMMP13 transcript
levels (Fig. 9E). MMP13 expression was upregulated by rhFGF2 (Fig.
9E), but this seemed to be associated with the maturation of
osteoblasts, as shown by the increase in OC expression in immature
osteoblasts. Moreover, although the expression levels of OC and Runx2
were not affected in osteoblasts, rhTGF-β1, rhTGF-β2, or rhTGF-β3
induced the upregulation of both MMP9 and MMP13 in these cells
(Fig. 9E). As shown in Fig. 9F, rhTGF-β2 could induce MMP9 expres-
sion in chondrocytes, but rmVEGF-A164, PTHrP, or rhBMP6 failed to
induce this gene. Activation of TGF-β signaling in chondrocytes or
osteoblasts was conﬁrmed by the detection of phosphorylated Smad2teoblasts isolated from the calvariae were seeded at 8×104 cells/well in 6-well plates in
or RCAS–VEGF-A166. After reaching conﬂuence, the cells were induced to differentiate for
GF-A166 (C) on day 8 is shown. (D) Total RNAwas extracted from immature osteoblasts
66. The expression of MMP2, MMP13, Col1a2, ALP, OP, OC, or env mRNA is shown. (E)
hTGF-β1 (10 ng/ml), rhTGF-β2 (10 ng/ml), rhTGF-β3 (10 ng/ml), rhBMP4 (500 ng/ml),
. Expression of MMP2, MMP9, MMP13, Col1a2, Runx2, or OC mRNA was examined by
105 cells per well in a 6-well plate andmaintained inαMEM containing 10% FBS. On day
0−8 M), or rhBMP6 (100 ng/ml) for 24 h, and total RNA was prepared. Northern blot
was loaded into each lane and the loading levels were veriﬁed by ethidium bromide
steo.) were treated with rhTGF-β2 (10 ng/ml) for 10 min. P-Smad2 or Smad2 in these
Fig. 10. Activation of TGF-β signaling during vascular invasion into cartilage. Semi-serial sections were prepared for toluidine blue staining (A, D, G, J) and immunostaining with anti-
P-Smad2 (C, F, I, L, N, P). At stage 32, perichondrial angiogenesis in the ulna is not observed in the left contralateral (A) and right VEGF-A122-overexpressing forelimb (D) but seen in
the VEGF-A166-overexpressing forelimb (G). Magniﬁed images corresponding to the boxed regions in (A, D, G) are shown as bright (B, E, H) or ﬂuorescence images (C, F, I). P-Smad2
positive cells are detectable in the vascularized perichondrial tissue and cartilage in the VEGF-A166-overexpressing forelimb (H, I), whereas these positive cells are not found in the
contralateral (B, C) or VEGF-A122-overexpressing forelimb (E, F). In a normal chick embryo, vascular invasion occurs at the center of the ulna at stage 37 (asterisk in J). The boxed
regions in (J) correspond to the areas shown in (K–P) (a yellow box for K, L, a green box for M, N, and an orange box for O, P). P-Smad2 positive cells are detectable in the vascular
invasion site (asterisk) near the bony collar (K, L) or the hypertrophic cartilage (M, N), but most of the proliferating chondrocytes are found to be P-Smad2 negative (O, P). u, ulna; ca,
cartilage; BF, bright ﬁeld; TB, toluidine blue. Scale bars, 100 μm.
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been reported previously that TGF-β1, TGF-β2, and TGF-β3 (TGF-βs)
are expressed in cartilaginous bone primordium in a normal embryo
at stage 37 (Alvarez et al., 2002). Indeed, TGF-β2 and TGF-β3 were
found to be expressed in cartilage and cultured osteoblasts in our
current experiments (Fig. S5), but VEGF-A166 failed to directly induce
the expression of any type of TGF-β isoform in osteoblasts (data not
shown).
To investigate whether a latent form of TGF-β is activated during
perichondrial angiogenesis and cartilage vascularization, we analyzed
the activation of TGF-β signaling in forelimbs overexpressing VEGF-
A122 or VEGF-A166, and a stage 37 normal forelimb, using a speciﬁc
antibody that recognizes P-Smad2. Contralateral to the VEGF-A122-
overexpressing forelimb at stage 32, blood vessels were found to
localize outside perichondrial tissue (Figs. 10A, B) and P-Smad2
positive cells were undetectable in both perichondrial tissue and
cartilage (Fig. 10C). Similarly, P-Smad2 positive cells were undetect-
able in the non-vascularized perichondrial tissue of the VEGF-A122-
overexpressing forelimb at stage 32 (Figs. 10D–F). In contrast, in the
VEGF-A166-overexpressing forelimb at stage 32, P-Smad2 positivecells were found in the vascularized perichondrial tissue including
cartilage of the ulna (Figs. 10G–I). In a normal forelimb, P-Smad2
positive cells were detected at the bony collar and the vascularized
cartilage at stage 37 (Figs. 10J–N). Although the articular surface and
the vascularized perichondrium were also found to be P-Smad2
positive (data not shown), P-Smad2 positive cells were only sparsely
present in the proliferating zone of cartilage (Figs. 10O, P). Hence, the
activation of TGF-β signaling is closely associated with perichondrial
angiogenesis and cartilage vascularization.
Discussion
Once the perichondrium is vascularized, blood vessels in direct
contact with the developing bony collar invade the center of the
hypertrophic cartilage accompanying osteoblasts and osteoclasts.
Even under accelerated conditions by overexpression of VEGF-A146,
VEGF-A166, or VEGF-A190, however, vascular invasion occurred only in
the middle of the cartilaginous shaft along with the bony collar (Figs.
3, 4). This suggests that the bony collar plays a signiﬁcant role in the
guidance of the vasculature from the perichondrium to the center of
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misexpressing cartilage that is surrounded by the ectopic bony collar
but lacks hypertrophic chondrocytes, vascular invasion was observed
at multiple sites along the immature cartilage. Cartilage in this case is
replaced by bone not from inside the center of cartilage but from
outside at multiple locations along immature cartilage (Vortkamp et
al., 1996). On the other hand, due to defects in perichondrial bony
collar formation, aberrant or delayed vascular invasion into cartilage
was previously observed in mice deﬁcient for Ihh or Osx (St-Jacques et
al., 1999; Nakashima et al., 2002). Moreover, cartilage vascularization
was found to be absent in Runx2 knockout mice lacking a bony collar
and hypertrophic cartilage (Zelzer et al., 2001). This defect was
rescued by the forced expression of Runx2 in cartilage of Runx2−/−
mice (Takeda et al., 2001). These results suggest that, following
perichondrial angiogenesis, the bony collar acts in concert with
hypertrophic cartilage to guide the vasculature into the center of the
diaphysis, ultimately leading to formation of the primary ossiﬁcation
center.
Both osteoblasts and hypertrophic chondrocytes express receptor
activator nuclear factor-kappaB ligand (RANKL) that activates nuclear
factor-κβ (NF-κβ) and nuclear factor of activated T cells c1 (NFATc1)
through the receptor activator of nuclear factor κβ (RANK), which is a
key regulator of osteoclast formation (Kartsogiannis et al., 1999). Since
hematopoietic osteoclast precursors express VEGFR-1 and RANK
(Gerber et al., 1999), these VEGF-A-responsive osteoclast precursors
seem to be attracted from the capillary and differentiate into MMP9-
positive osteoclasts on the bony collar and hypertrophic cartilage,
probably via activation of the RANK/RANKL pathway. In VEGF-A122-
overexpressing forelimb where the vasculature is located outside
perichondrial tissue, neither MMP9- nor MMP13-positive cells were
observed (Fig. 3), implying that a direct interaction between
osteoclast precursors and perichondrial osteoblasts on the bony collar
is essential for the appearance of MMP9-positive osteoclasts and
MMP13-positive skeletal cells. These ﬁndings thus highlight the
signiﬁcance of the bony collar as an active site for osteoclastogenesis
that correctly guides the perichondrial vasculature into the cartilage
center.
MMP9 and MMP13 synergistically degrade and remodel the
cartilage ECM after perichondrial angiogenesis, a process that is itself
not signiﬁcantly affected by these MMPs (Engsig et al., 2000; Ortega
et al., 2003; Stickens et al., 2004; Vu et al., 1998). In normal (Figs. S4C–
E) or accelerated (Figs. 4P–U) vascularized cartilage, MMP9 was
observed to be expressed in TRAP-positive osteoclasts as well as
osteoblasts or chondrocytes, some of which expressMMP13. As shown
in Fig. S1B, VEGFR-1 or VEGFR-2 could be also detected in osteoblasts
and chondrocytes, but it remains controversial as to whether VEGF-A
directly acts on non-endothelial cells such as skeletal cells. Although
the facilitation of mineralization in osteoblasts in vitro has been
previously reported (Zelzer et al., 2002), no signiﬁcant change in
mineral deposition was observed between VEGF-A166- and EGFP-
overexpressing osteoblasts (data not shown), consistent with our
current in vitro evidence that neither VEGF-A166 overexpression nor
the addition of rhVEGF-A165 in osteoblasts affects the mRNA levels of
osteoblastic marker genes such as ALP, OP, and OC (Figs. 9D, E).
Similarly, upon overexpression of VEGF-A166 or the addition of
rhVEGF-A165, neither MMP9 nor MMP13 was found to be upregulated
in osteoblasts (Figs. 9D, E). Instead, we observed that TGF-βs could
induce MMP9 expression in osteoblasts or chondrocytes, and MMP13
expression in osteoblasts (Figs. 9E, F), via the Smad pathway (Fig. 9G).
TGF-βs play an important role in the Ihh–PTHrP signal relay that
regulates chondrocyte differentiation (Alvarez et al., 2002). TGF-β also
promotes osteoclastogenesis in monocytes by stimulating p38 MAPK
(Karsdal et al., 2003) and modulates the expression of VEGF-A by
osteoblasts (Saadeh et al., 1999). Both chondrocytes and osteoblasts
produce TGF-βs that are sequestered in the ECM as latent forms
(Alvarez et al., 2002; Annes et al., 2003). These bone matrix-boundTGF-βs were previously shown to be released by osteoclasts via LTBP1
(latent TGF-β binding protein 1) cleavage (Dallas et al., 2002). The
released TGF-βs can then be activated by MMP9 (Karsdal et al., 2003;
Yu and Stamenkovic, 2000). As in the case of VEGF-A stored in
hypertrophic cartilage matrix and inducible by MMP9 (Engsig et al.,
2000), it is thus conceivable that TGF-βs in the perichondrium or
cartilage could also be activated by MMP9-positive osteoclasts. This
would in turn lead to the induction of MMP9 or MMP13 expression in
osteoblasts and chondrocytes, which facilitates efﬁcient ECM remo-
deling in concert with osteoclasts. Indeed, we demonstrate herein that
the activation of TGF-β signaling was only observed in the vascular-
ized perichondrial tissue and cartilage as well as the bony collar (Fig.
10). Since the timing ofMMP9 expressionwas found to be earlier than
that of MMP13 (data not shown) and the area of its expression was
wider (Fig. 3J), we speculate that VEGF-A responsive osteoclast
precursors recruited from the circulatory system are initially involved
in the activation of latent TGF-βs and then induce MMP9/13
expression in osteoblasts and chondrocytes. Our current analyses
thus suggest an additional and signiﬁcant role of the TGF-βs in the
induction of MMP9 and MMP13 expression in skeletal cells during
endochondral bone formation.
Perichondrial tissue had previously been recognized in histological
studies as simply an avascular noncartilaginous region surrounding
cartilage. However, gain of function studies from our laboratory have
revealed that perichondrial tissue also plays a key role as a robust anti-
angiogenic barrier. Similar to the surrounding vascularized connective
tissue, perichondrial tissue lacks the cartilaginous matrices that
characterize extracellular components such as aggrecan, type II
collagen, and also a cartilage derived angiogenesis inhibitor chon-
dromodulin-I (Shukunami et al., 2008). A strong level of perichondrial
resistance to VEGF-A-driven vascular invasion was found in our
current study, comparable to that of cartilage. In transgenic mice
overexpressing VEGF-A164 in cartilage, perichondrial tissue and
cartilage remained avascular against a concentration gradient of
VEGF-A164 (Fig. 1).
With the exception of the epiphyseal articular surface, the
tenascin-positive inner layer of avascular perichondrial tissue formed
the perichondrium that was eventually vascularized by attracting
blood vessels from outside areas (Fig. 3). The anti-angiogenic
properties of perichondrial tissue suggest that blood vessels must
overcome and pass through this outer anti-angiogenic barrier to form
the vascularized perichondrium, thereby making direct contact with
the developing bony collar. Although perichondrial angiogenesis is a
prerequisite for the subsequent vascular invasion of cartilage, little has
been elucidated thus far regarding its regulation. In our present study,
however, we have identiﬁed differential vascular responses of
perichondrial tissue to VEGF-A isoforms during perichondrial angio-
genesis i.e. heparin and Nrp-binding VEGF-A isoforms (VEGF-A146,
VEGF-A166, VEGF-A190) can accelerate the migration of endothelial
cells into the perichondrium, whereas non-heparin binding and freely
diffusible VEGF-A122 fails to do so (Fig. 11A).
Recently, Eshkar-Oren et al. (2009) have reported that prior to the
generation of cartilage the avascular condensing limb mesenchyme
acts as a signaling center for the patterning of the limb vasculature via
the regulation of VEGF-A. This is compatible with our present
observation that only the limb mesenchyme away from perichondrial
tissue and cartilagewas permissive for angiogenesis at the early stages
of endochondral bone formation. Previous analysis of mice harboring
a LacZ insert at the 3′UTR of VEGF-A and in situ hybridization analysis
revealed that VEGF-A is initially expressed in the condensing
mesenchyme and later in hypertrophic chondrocytes (Zelzer et al.,
2002; Eshkar-Oren et al., 2009). This biphasic expression proﬁle may
reﬂect two distinct roles of VEGF-A: The initial induction of VEGF-A is
mainly to promote limb vasculature patterning, whereas the later
upregulation of VEGF-A in hypertrophic chondrocytes drives peri-
chondrial angiogenesis and subsequent cartilage vascularization.
Fig. 11. Differential regulation of perichondrial angiogenesis by VEGF-A isoforms. (A) In association with the appearance of Ihh-positive prehypertrophic chondrocytes and the bony
collar, VEGF-A146, VEGF-A166, VEGF-A190, or VEGF-A166R125A/R160A can induce perichondrial angiogenesis, followed by the induction of MMP9 and MMP13 along the bony collar
(lower side under the black line in A). In contrast, VEGF-A122 and VEGF-A166ΔE162-R166 fail to attract the vasculature into the perichondrium (upper side in A). (B) A two-step model of
angiogenesis during endochondral bone formation. The ﬁrst step of angiogenesis (perichondrial angiogenesis) is regulated by VEGF-A146, VEGF-A166, and VEGF-A190, all of which have
the ability to interact with both HSPGs and Nrps (1). Once the vasculature becomes accessible to the bony collar, osteoclast precursors are recruited from the circulating blood cells in
response to VEGF-A and differentiate intoMMP9-positive osteoclasts (2). Prior to the second step of angiogenesis (cartilage vascularization),MMP9-positive osteoclasts activate TGF-
βs that are abundantly expressed and stored in the ECM of the perichondrial osteoblasts (3). The TGF-β isoforms stimulate chondrocytes and osteoblasts to express MMP9 and
MMP13, thus further facilitating vascular invasion, excavation and remodeling of the ECM (4).
209A. Takimoto et al. / Developmental Biology 332 (2009) 196–211HSPGs act as both regulators of the VEGF-A gradient and as co-
receptors that facilitate the formation of the active signaling complex
in vascular endothelial cells (Olsson et al., 2006). It has been revealed
that a presentation of VEGF-A165 to VEGFR-2 in trans by HSPGs that are
expressed on adjacent pericytes, enables a marked increase in signal
amplitude and duration (Jakobsson et al., 2006). HSPGs such as
syndecan and perlecan are abundantly expressed in cartilage and the
perichondrium (Hardingham and Fosang,1992), raising the possibility
that HSPG-positive perichondrial cells or ECM-bound HSPGs guide
blood vessels into the perichondrium. However, despite their
potential as enhancers of signaling through VEGFR-2, it is unlikely
that HSPGs directly activate the angiogenic switch since these factors
are also expressed in perichondrial tissue surrounding the non-
hypertrophic cartilage (Koyama et al., 1995). Indeed, the VEGF-A166
mutant with an impaired heparin-binding capability induced hyper-
vascularization in the surrounding connective tissue less efﬁciently,
but still promoted the acceleration of perichondrial angiogenesis
(Fig. 6).
When the VEGF-A166 deletion mutant also lacked the Nrp-binding
motif (VEGF-A166ΔE162-R166), this protein completely lost its ability to
accelerate perichondrial angiogenesis, but could still induce hyper-
vascularization in the surroundingmesenchyme (Fig. 8). This suggests
a pivotal role for Nrp in perichondrial angiogenesis. Nrps act as co-
receptors of VEGF-A in vascular endothelial cells, probably by affecting
the half-life of the receptor complex (Olsson et al., 2006). In the
developing central nervous system, Nrp1 has been reported to be
required for endothelial tip cell guidance (Gerhardt et al., 2004). The
increased expression of Nrp1 in blood vessels and surrounding cells
was observed in our current analyses in the forelimb overexpressing
VEGF-A122 or VEGF-A166 (Fig. 7), whilst the overexpression of theseVEGF-A isoforms did not alter Nrp2 expression signiﬁcantly (data not
shown). These ﬁndings are consistent with the previously reported in
vitro evidence that VEGF-A selectively upregulates Nrp1 but not Nrp2
in blood vessels (Oh et al., 2002). Since VEGF-A122 is unable to interact
with Nrps, upregulated Nrp1may potentiate the angiogenesis induced
by VEGF-A166, which is an Nrp-binding VEGF-A isoform.
Nrp2 was also found to be predominantly expressed in the entire
perichondrial region (Fig. S3E), whereas Nrp1 expression was
detected in the region corresponding to the developing bony collar
(Fig. S3D). As previously demonstrated in tumor cells (Bielenberg
et al., 2004), Nrps that are expressed on perichondrial cells may
stabilize the VEGF-A/VEGFR signaling complex in trans. Interestingly,
Sema3F, another ligand of the Nrps, was also detected in perichondrial
tissue in our experiments (Fig. S3F). Semaphorins compete with VEGF-
A for binding to Nrp1/2, thereby preventing Nrp1 or Nrp2 from
associating with VEGFR-1 and VEGFR-2. Given that Sema3F can inhibit
tumor angiogenesis (Bielenberg et al., 2004), it is possible that this
molecule also contributes to the anti-angiogenic properties of peri-
chondrial tissue by counteracting its VEGF-A driven angiogenic activity.
In conclusion,wedemonstrate in our current study for theﬁrst time
that perichondrial tissue acts as a robust anti-angiogenic barrier. We
also provide strong evidence that the switching of the vascular
phenotype from anti-angiogenic to angiogenic is regulated by VEGF-A
isoforms that have the ability to interact with the Nrps and HSPGs (Fig.
11A). Following perichondrial angiogenesis, osteoclast precursors are
recruited from blood vessels to the bony collar to differentiate into
MMP9-positive osteoclasts. These cells can then activate latent TGF-
βs to further induce MMP9- and MMP13-positive osteoblasts and
chondrocytes for the excavation and remodeling of the ECM, thus
enabling the progression of the vascular invasion of cartilage (Fig.11B).
210 A. Takimoto et al. / Developmental Biology 332 (2009) 196–211Acknowledgments
We thank N. Tsumaki, T. Ogura, A. Lassar, and BR. Olsen for
providing p742-Int vector, env cDNA, Runx2 cDNA, and the Col1a2 and
Col2a1 cDNAs, respectively. We also thank T. Ogura and Y. Kida for
advice on in ovo electroporation methodology. This study was partly
supported by Grants-in-Aid from the Ministry of Education, Culture,
Sport, Science and Technology of Japan, and by the Tanabe Medical
Frontier Conference.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ydbio.2009.05.552.
References
Alvarez, J., Sohn, P., Zeng, X., Doetschman, T., Robbins, D.J., Serra, R., 2002. TGFbeta2
mediates the effects of hedgehog on hypertrophic differentiation and PTHrP
expression. Development 129, 1913–1924.
Annes, J.P., Munger, J.S., Rifkin, D.B., 2003. Making sense of latent TGFbeta activation.
J. Cell Sci. 116, 217–224.
Bielenberg, D.R., Hida, Y., Shimizu, A., Kaipainen, A., Kreuter, M., Kim, C.C., Klagsbrun, M.,
2004. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly
vascularized, encapsulated, nonmetastatic tumor phenotype. J. Clin. Invest. 114,
1260–1271.
Carmeliet, P., Jain, R.K., 2000. Angiogenesis in cancer and other diseases. Nature 407,
249–257.
Colnot, C., 2005. Cellular and molecular interactions regulating skeletogenesis. J. Cell
Biochem. 95, 688–697.
Dallas, S.L., Rosser, J.L., Mundy, G.R., Bonewald, L.F., 2002. Proteolysis of latent
transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A
cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277,
21352–21360.
Engsig, M.T., Chen, Q.J., Vu, T.H., Pedersen, A.C., Therkidsen, B., Lund, L.R., Henriksen, K.,
Lenhard, T., Foged, N.T., Werb, Z., Delaisse, J.M., 2000. Matrix metalloproteinase 9
and vascular endothelial growth factor are essential for osteoclast recruitment into
developing long bones. J. Cell Biol. 151, 879–889.
Eshkar-Oren, I., Viukov, S.V., Salameh, S., Krief, S., Oh, C.D., Akiyama, H., Gerber, H.P.,
Ferrara, N., Zelzer, E., 2009. The forming limb skeleton serves as a signaling center
for limb vasculature patterning via regulation of Vegf. Development 136,
1263–1272.
Flamme, I., von Reutern, M., Drexler, H.C., Syed-Ali, S., Risau, W.,1995. Overexpression of
vascular endothelial growth factor in the avian embryo induces hypervasculariza-
tion and increased vascular permeability without alterations of embryonic pattern
formation. Dev. Biol. 171, 399–414.
Folkman, J., 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat.
Med. 1, 27–31.
Gerber, H.P., Vu, T.H., Ryan, A.M., Kowalski, J., Werb, Z., Ferrara, N., 1999. VEGF couples
hypertrophic cartilage remodeling, ossiﬁcation and angiogenesis during endochon-
dral bone formation. Nat. Med. 5, 623–628.
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A.,
Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., Betsholtz, C., 2003. VEGF guides
angiogenic sprouting utilizing endothelial tip cell ﬁlopodia. J. Cell Biol. 161,
1163–1177.
Gerhardt, H., Ruhrberg, C., Abramsson, A., Fujisawa, H., Shima, D., Betsholtz, C., 2004.
Neuropilin-1 is required for endothelial tip cell guidance in the developing central
nervous system. Dev. Dyn. 231, 503–509.
Gerstenfeld, L.C., Chipman, S.D., Glowacki, J., Lian, J.B., 1987. Expression of differ-
entiated function by mineralizing cultures of chicken osteoblasts. Dev. Biol. 122,
49–60.
Haigh, J.J., Gerber, H.P., Ferrara, N., Wagner, E.F., 2000. Conditional inactivation of VEGF-
A in areas of collagen2a1 expression results in embryonic lethality in the
heterozygous state. Development 127, 1445–1453.
Hallmann, R., Feinberg, R.N., Latker, C.H., Sasse, J., Risau, W., 1987. Regression of blood
vessels precedes cartilage differentiation during chick limb development.
Differentiation 34, 98–105.
Hamburger, V., Hamilton, H.L., 1992. A series of normal stages in the development of the
chick embryo. 1951. Dev. Dyn. 195, 231–272.
Hardingham, T.E., Fosang, A.J., 1992. Proteoglycans: many forms and many functions.
FASEB J. 6, 861–870.
Herve, M.A., Buteau-Lozano, H., Vassy, R., Bieche, I., Velasco, G., Pla, M., Perret, G.,
Mourah, S., Perrot-Applanat, M., 2008. Overexpression of vascular endothelial
growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated
intratumoral vessels. Am. J. Pathol. 172, 167–178.
Hiraki, Y., Inoue, H., Iyama, K., Kamizono, A., Ochiai, M., Shukunami, C., Iijima, S., Suzuki,
F., Kondo, J., 1997. Identiﬁcation of chondromodulin I as a novel endothelial cell
growth inhibitor. Puriﬁcation and its localization in the avascular zone of
epiphyseal cartilage. J. Biol. Chem. 272, 32419–32426.Hogan, B., Beddington, R., Costantini, F., Lacy, E., 1994. Manipulating the Mouse
Embryo: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, New
York.
Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J., Ferrara, N., 1992. Dual regulation of
vascular endothelial growth factor bioavailability by genetic and proteolytic
mechanisms. J. Biol. Chem. 267, 26031–26037.
Jakobsson, L., Kreuger, J., Holmborn, K., Lundin, L., Eriksson, I., Kjellen, L., Claesson-
Welsh, L., 2006. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis.
Dev. Cell 10, 625–634.
Jia, H., Bagherzadeh, A., Hartzoulakis, B., Jarvis, A., Lohr, M., Shaikh, S., Aqil, R.,
Cheng, L., Tickner, M., Esposito, D., Harris, R., Driscoll, P.C., Selwood, D.L.,
Zachary, I.C., 2006. Characterization of a bicyclic peptide neuropilin-1 (NP-1)
antagonist (EG3287) reveals importance of vascular endothelial growth factor
exon 8 for NP-1 binding and role of NP-1 in KDR signaling. J. Biol. Chem. 281,
13493–13502.
Karsdal, M.A., Hjorth, P., Henriksen, K., Kirkegaard, T., Nielsen, K.L., Lou, H., Delaisse, J.M.,
Foged, N.T., 2003. Transforming growth factor-beta controls human osteoclasto-
genesis through the p38 MAPK and regulation of RANK expression. J. Biol. Chem.
278, 44975–44987.
Karsenty, G., Wagner, E.F., 2002. Reaching a genetic and molecular understanding of
skeletal development. Dev. Cell 2, 389–406.
Kartsogiannis, V., Zhou, H., Horwood, N.J., Thomas, R.J., Hards, D.K., Quinn, J.M., Niforas,
P., Ng, K.W., Martin, T.J., Gillespie, M.T., 1999. Localization of RANKL (receptor
activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal
tissues. Bone 25, 525–534.
Koyama, E., Leatherman, J.L., Shimazu, A., Nah, H.D., Paciﬁci, M., 1995. Syndecan-3,
tenascin-C, and the development of cartilaginous skeletal elements and joints in
chick limbs. Dev. Dyn. 203, 152–162.
Krilleke, D., DeErkenez, A., Schubert, W., Giri, I., Robinson, G.S., Ng, Y.S., Shima, D.T.,
2007. Molecular mapping and functional characterization of the VEGF164 heparin-
binding domain. J. Biol. Chem. 282, 28045–28056.
Kuettner, K.E., Pauli, B.U., 1983. Vascularity of cartilage. In: Hall, B.K. (Ed.), Cartilage, 1.
Academic Press, New York, pp. 281–312.
Maes, C., Carmeliet, P., Moermans, K., Stockmans, I., Smets, N., Collen, D., Bouillon, R.,
Carmeliet, G., 2002. Impaired angiogenesis and endochondral bone formation in
mice lacking the vascular endothelial growth factor isoforms VEGF164 and
VEGF188. Mech. Dev. 111, 61–73.
Maes, C., Stockmans, I., Moermans, K., Van Looveren, R., Smets, N., Carmeliet, P.,
Bouillon, R., Carmeliet, G., 2004. Soluble VEGF isoforms are essential for establish-
ing epiphyseal vascularization and regulating chondrocyte development and
survival. J. Clin. Invest. 113, 188–199.
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R., de
Crombrugghe, B., 2002. The novel zinc ﬁnger-containing transcription factor
osterix is required for osteoblast differentiation and bone formation. Cell 108,
17–29.
Ogura, T., 2002. In vivo electroporation: a new frontier for gene delivery and
embryology. Differentiation 70, 163–171.
Oh, H., Takagi, H., Otani, A., Koyama, S., Kemmochi, S., Uemura, A., Honda, Y., 2002.
Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a
mechanism contributing to VEGF-induced angiogenesis. Proc. Natl. Acad. Sci. U. S. A.
99, 383–388.
Olsson, A.K., Dimberg, A., Kreuger, J., Claesson-Welsh, L., 2006. VEGF receptor signalling
— in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359–371.
Ortega, N., Behonick, D., Stickens, D., Werb, Z., 2003. How proteases regulate bone
morphogenesis. Ann. N. Y. Acad. Sci. 995, 109–116.
Saadeh, P.B., Mehrara, B.J., Steinbrech, D.S., Dudziak, M.E., Greenwald, J.A., Luchs, J.S.,
Spector, J.A., Ueno, H., Gittes, G.K., Longaker, M.T., 1999. Transforming growth
factor-beta1 modulates the expression of vascular endothelial growth factor by
osteoblasts. Am. J. Physiol. 277, C628–C637.
Sasaki, H., Hui, C., Nakafuku, M., Kondoh, H., 1997. A binding site for Gli proteins is
essential for HNF-3beta ﬂoor plate enhancer activity in transgenics and can respond
to Shh in vitro. Development 124, 1313–1322.
Shibuya, M., Claesson-Welsh, L., 2006. Signal transduction by VEGF receptors in
regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549–560.
Shukunami, C., Takimoto, A., Oro, M., Hiraki, Y., 2006. Scleraxis positively regulates the
expression of tenomodulin, a differentiation marker of tenocytes. Dev. Biol. 298,
234–247.
Shukunami, C., Takimoto, A., Miura, S., Nishizaki, Y., Hiraki, Y., 2008. Chondromodulin-I
and tenomodulin are differentially expressed in the avascular mesenchyme during
mouse and chick development. Cell Tissue Res. 332, 111–122.
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., Klagsbrun, M., 1998. Neuropilin-1 is
expressed by endothelial and tumor cells as an isoform-speciﬁc receptor for
vascular endothelial growth factor. Cell 92, 735–745.
Staton, C., Kumar, I., Reed, M., Brown, N., 2007. Neuropilins in physiological and
pathological angiogenesis. J. Pathol. 212, 237–248.
Stickens, D., Behonick, D.J., Ortega, N., Heyer, B., Hartenstein, B., Yu, Y., Fosang, A.J.,
Schorpp-Kistner, M., Angel, P., Werb, Z., 2004. Altered endochondral bone
development in matrix metalloproteinase 13-deﬁcient mice. Development 131,
5883–5895.
St-Jacques, B., Hammerschmidt, M., McMahon, A.P., 1999. Indian hedgehog signaling
regulates proliferation and differentiation of chondrocytes and is essential for bone
formation. Genes Dev. 13, 2072–2086.
Takeda, S., Bonnamy, J.P., Owen, M.J., Ducy, P., Karsenty, G., 2001. Continuous expression
of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce
hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deﬁcient
mice. Genes Dev. 15, 467–481.
211A. Takimoto et al. / Developmental Biology 332 (2009) 196–211Tsumaki, N., Kimura, T., Matsui, Y., Nakata, K., Ochi, T., 1996. Separable cis-regulatory
elements that contribute to tissue- and site-speciﬁc alpha 2(XI) collagen gene
expression in the embryonic mouse cartilage. J. Cell Biol. 134, 1573–1582.
Tsumaki, N., Nakase, T., Miyaji, T., Kakiuchi, M., Kimura, T., Ochi, T., Yoshikawa, H., 2002.
Bone morphogenetic protein signals are required for cartilage formation and
differently regulate joint development during skeletogenesis. J. Bone Miner. Res. 17,
898–906.
von Wronski, M.A., Tweedle, M.F., Nunn, A.D., 2007. Binding of the C-terminal amino
acids of VEGF121 directly with neuropilin-1 should be considered. FASEB J. 21, 1292
author reply 1293.
Vortkamp, A., Lee, K., Lanske, B., Segre, G.V., Kronenberg, H.M., Tabin, C.J., 1996.
Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related
protein. Science 273, 613–622.Vu, T.H., Shipley, J.M., Bergers, G., Berger, J.E., Helms, J.A., Hanahan, D., Shapiro,
S.D., Senior, R.M., Werb, Z., 1998. MMP-9/gelatinase B is a key regulator of
growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93,
411–422.
Yu, Q., Stamenkovic, I., 2000. Cell surface-localized matrix metalloproteinase-9
proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.
Genes Dev. 14, 163–176.
Zelzer, E., Glotzer, D.J., Hartmann, C., Thomas, D., Fukai, N., Soker, S., Olsen, B.R., 2001.
Tissue speciﬁc regulation of VEGF expression during bone development requires
Cbfa1/Runx2. Mech. Dev. 106, 97–106.
Zelzer, E., McLean, W., Ng, Y.S., Fukai, N., Reginato, A.M., Lovejoy, S., D'Amore, P.A., Olsen,
B.R., 2002. Skeletal defects in VEGF(120/120)mice reveal multiple roles for VEGF in
skeletogenesis. Development 129, 1893–1904.
